Brain Tumor
Conditions
Brief summary
Glioblastoma is the most frequent and aggressive primary brain tumor in adults. A team recently showed that baseline plasma levels of matrix metalloproteinase-2 (MMP2) and matrix metalloproteinase-9 (MMP9) were correlated to bevacizumab activity in patients with recurrent glioblastoma. To date, the biological rationale of this results remains unknown but MMP2 could be involved in classical angiogenesis while MMP9 could promote vasculogenesis. The objectives are to correlate the plasma levels of MMP2 and MMP9 to their Ribonucleic acid (RNA) and protein tissue expression, activity and to patient neuro-imaging features. To analyze the changes of MMP2 and MMP9 plasma levels during peri-operative period and after radio-chemotherapy. Methods: Plasmatic levels of MMP2, MMP9, vascular endothelial growth factor-A (VEGFA), vascular endothelial growth factor-R2 (VEGFR2), stromal cell-derived factor 1 (SDF1) and chemokine receptor-4 (CXCR4) will be analyzed by enzyme-linked immunosorbent assay (ELISA) in pre-, post-operative period, before radiotherapy, before adjuvant temozolomide and at relapse in newly diagnosed glioblastoma. RNA expression of these factors will be analyzed by reverse transcription-Polymerase chain reaction (RT-qPCR) on frozen tumor samples, whereas protein expression will be analyzed by ELISA and immunohistochemistry. Enzymatic activity of MMP2 and MMP9 will be analyzed by zymography. Tumor volume, infiltration and perfusion degrees will be analyzed on Magnetic Resonance Imaging (MRI) performed before and after surgery and before adjuvant temozolomide. Neuro-imaging characteristics will be correlated to plasma and tissue expressions of these factors. The expected results are to better define the expression profile of MMP2, MMP9 and the change in their plasma level during treatment, a prerequisite for their clinical use.
Interventions
BIOLOGICALBlood sample
Five blood sample in pre-, post-operative period, before radiotherapy, before adjuvant temozolomide and at relapse in newly diagnosed glioblastoma
BIOLOGICALTumor sample
One tumor sample in operative period
Sponsors
Assistance Publique Hopitaux De Marseille
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient, male or female, aged 18 years or over * Imaging suggestive of glioblastoma * Patient eligible for excision surgery (partial, subtotal or macroscopically complete) * Candidate for concomitant and adjuvant radiotherapy chemotherapy (Stupp protocol) * Patient having signed an informed consent * Patient having undergone a preoperative MRI
Exclusion criteria
* Existence of a contraindication to the MRI * Nonoperable lesion * History of radiotherapy and / or chemotherapy for this lesion * Scalability of a low grade lesion * Person in emergency situation, a legal person of legal age (guardianship, guardianship or legal guardianship), or unable to express his or her consent * No affiliation to a social security scheme (beneficiary or beneficiary) * Pregnant or lactating woman
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| correlate the plasma levels of MMP2 and MMP9 to their RNA and protein tissue expression by ELISA | 18 months | identify potential temporal variations of these markers |
Countries
France
Contacts
CONTACTEmeline TABOURET, PH
CONTACTDominique FIGARELLA, PU-PH
STUDY_DIRECTORJean-Olivier ARNAUD, Director
Assistance Publique Hôpitaux de Marseille
Outcome results
None listed